Heat Shock Protein 75 (TRAP1) Antagonizes Reactive Oxygen Species Generation and Protects Cells from Granzyme M-mediated Apoptosis*

Guoqiang Hua, Qixiang Zhang, and Zusen Fan

From the National Laboratory of Biomacromolecules and Center for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

Cytotoxic T lymphocytes (CTLs)\(^2\) and natural killer (NK) cells are effector lymphocytes that are necessary for defense against virus-infected or transformed cells (1, 2). These cytolytic lymphocytes use the granule exocytosis pathway, which release perforin (PFP) and granzymes (Gzms) from cytolytic granules into an immunological synapse formed with their target (3). GzmA and B are the most abundant Gzms in mice and humans and have been most extensively studied (4–8). However, less is known about how other Gzms work in granule-mediated apoptosis. These Gzms are called orphan Gzms, which are also highly conserved serine proteases found in both humans and rodents, located in three clusters on separate chromosomes. The orphan Gzms include C, D, E, F, G, K, L, M, and N in mice, and H, K, and M in humans (9). GzmM is an orphan Gzmn that cleaves preferentially after methionine, leucine, or norleucine (10). GzmM is constitutively highly expressed in NK cells, whereas it is not expressed in CD4\(^+\) or CD8\(^+\) T cells either constitutively or after stimulation (11). Kelly et al. (12) reported that GzmM induces a novel form of perforin-dependent death without caspase activation and DNA fragmentation. However, we recently demonstrated that GzmM induces caspase-dependent apoptosis with DNA fragmentation through direct cleavage of inhibitor of caspase-activated DNase (ICAD). Moreover, GzmM degrades the DNA damage sensor enzyme PARP to prevent cellular DNA repair and force apoptosis.

Reactive oxygen species (ROS) are potent inducers of oxidative damage and have been proposed as critical regulators of apoptosis (14). ROS can induce opening of the permeability transition (PT) pore through oxidation-dependent mechanisms and are potent inducers of apoptosis, both in cultured cells and in vivo (14). Notably, intracellular ROS arise prior to cytochrome c (cyt c) release during the activation of several apoptosis pathways. Mitochondrial damage is a required initial step in caspase-dependent apoptosis, including that induced by Gzmb, in which it is triggered by proteolytic cleavage of Bid (15–17). GzmB and GzmC can also induce mitochondrial damage independently of the caspases (18–20). Lieberman and coworkers (21) recently reported that Gzma induces a rapid increase of ROS and mitochondrial transmembrane potential loss, but does not cleave Bid or cause apoptogenic factor release. Kelly et al. (12) reported GzmM changed the morphology of mitochondria to be rounded but not to be dilated. However GzmM does not alter the mitochondrial transmembrane potential (\(\Delta \Psi\)) or does not cause ROS accumulation and release of cyt c. It is unclear whether mitochondria are involved in GzmM-mediated apoptosis.

Tumor necrosis factor receptor-associated protein 1 (TRAP1) was initially identified using the yeast two-hybrid system as a novel protein that interacts with the intracellular domain of type I TNF receptor (22). TRAP1 is identical to heat shock protein 75 (HSP75), which is a member of the HSP90 family that binds to the retinoblastoma protein during mitosis and after heat shock (23). TRAP1 localizes in mitochondria and...
HSP75/TRAP1 Protects GzmM-mediated Apoptosis

its mitochondrial localization sequence exists at the N terminus of this protein (24). A recent report showed TRAP1 is dramatically suppressed in tumor cells with apoptogenic inducers, such as the shikonin derivative β-hydroxyisovalerylshikonin (β-HIV5) or a topoisomerase II inhibitor VP16. TRAP1 silencing enhances cyt c release and apoptosis induced by those two apoptotic inducers (25). Im et al. (26) showed TRAP1-overexpressing cells decrease ROS generation after treatment of the deeroxamine. These data suggest TRAP1 may play an important role in antagonizing apoptosis via reducing ROS accumulation. In this study, we demonstrated GzmM can cause mitochondrial swelling and loss of ∆Ψ. Furthermore, GzmM induces a rapid increase of intracellular ROS and the release of cyt c. TRAP1 is able to protect cells from death through inhibition of ROS generation. GzmM directly cleaves TRAP1 resulting in intracellular ROS accumulation. Moreover, cells with silenced TRAP1 expression are more susceptible, whereas cells overexpressing TRAP1 are more resistant to GzmM-induced apoptosis.

MATERIALS AND METHODS

Cell Lines, Antibodies, and Reagents—Cells were grown in RPMI 1640 (Jurkat) or DMEM medium (HeLa) supplemented with 10% fetal calf serum, 50 μM β-mercaptoethanol, 100 units/ml penicillin, and streptomycin. Commercial antibodies were mouse mAb against cytochrome c (BD Pharmingen), β-actin, horseradish peroxidase-conjugated sheep anti-mouse IgG (Santa Cruz) and Alexa488-conjugated donkey anti-mouse IgG (Molecular Probes). A monoclonal antibody against human TRAP1 (TRAP1–6) was kindly provided by Drs. D. O. Toft and S. J. Felts (Mayo Graduate School, Rochester, MN) or obtained from Abcam Ltd (Cambridge, UK). The fluorescent probe, 2',7'-dichlorofluorescin diacetate (DCF-DA) was from Molecular Probes, 4,5-Dihydroxyl-1,3-benzene-disulfonic acid (Tiron) and cyclosporine A (CsA) were from Sigma. LipofectamineTM2000 was from Invitrogen. Annexin V-FITC was from BD Pharmingen, ProLong Antifade kit was from Molecular Probes. ATPase Activity Assay—Recombinant GzmM, S-AGzmM (enzymatically inactive GzmM produced by mutating the active site Ser182 to Ala) were produced and purified as previously described (13). Full-length cDNA coding human TRAP1 (a gift from S. J. Felts) was subcloned into pET26b (+) and expressed in Escherichia coli strain BL21 (DE3). Recombinant TRAP1 with His6 tags were purified through a nickel column as above.

Loading GzmM with Adenovirus—Cells were washed three times in HBSS and resuspended in loading buffer (HBSS with 0.5 mg of bovine serum albumin per ml, 1 mM CaCl2, 1 mM MgCl2). HeLa cells or Jurkat cell (2 × 105) in 50 μl of loading buffer were incubated at 37 °C for the indicated times with different concentrations of GzmM, S-AGzmM, and an optimal dose of adenovirus (Ad). Cells were incubated for an additional 15 min in 1 mM phenylmethylsulfonyl fluoride before being lysed for immunoblot.

Transmission Electron Microscopy—HeLa cells (5 × 106) were treated with GzmM plus Ad at 37 °C for 4 h. Then cells were washed twice and fixed with 2% glutaraldehyde at 4 °C for 1 h and postfixed with 2% osmium tetroxide. Cells were dehydrated with sequential immerse in 50, 70, 80, 90, and 100% ethanol, and then embedded in Spurr’s resin. Ultrathin sections were mounted in copper grids and counterstained with uranyl acetate and lead citrate. Images were photographed and scanned by Eversmart Jazz + program (Scitex).

Assessment of ∆Ψ—For ∆Ψ, cells treated with GzmM/Ad or CCCP were stained with DiOC6 (3) and analyzed by flow cytometry as described (27). In brief, Jurkat cells treated with GzmM/Ad (100 pfu/ml) for the indicated times and doses were harvested and washed with HBSS three times. Cells were loaded with 20 μM 3,3'-dihexyloxacarbocyanine iodide DiOC6 (3) for 5 min before FACS analysis. Cells treated with the membrane uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) were used as a positive control.

Cleavage Assay—Cell lysates prepared from HeLa cells treated with Nonidet P-40 lysis buffer (0.5% Nonidet P-40/25 mM KCl/5 mM MgCl2/1 mM phenylmethylsulfonyl fluoride/10 mM Tris–HCl, pH 7.6). Cell lysates (equivalent to 2 × 105 cells) or 1 μM rTRAP was incubated with indicated doses of GzmM or S-AGzmM for the indicated time points in 20 μl of cleavage buffer (50 mM Tris–HCl pH 7.5, 1 mM CaCl2, 1 mM MgCl2). For in vivo cleavage assay, cells loaded with GzmM/Ad were lysed in 0.5% Nonidet P-40 lysis buffer. The reaction samples were terminated in 5 × SDS-loading buffer and probed by immunoblotting.

ATPase Activity Assay—ATP hydrolysis was measured directly by the conversion of ATP to ADP, release of inorganic phosphate (P) was estimated according to Kempaiah and Srini-vasan (28). Briefly, TRAP1 (3 μM) was incubated with 1 mM ATP at 37 °C for indicated times in 100 μl of buffer containing 10 mM Hepes-KOH, pH 7.4, and 5 mM MgCl2, 120 mM KCl. Inhibition by granzyme M was performed with 3 μM TRAP1, 1 mM ATP, and various amounts of granzyme M. Reactions were stopped by addition of 200 μl of 1% SDS. Following treatment, samples (0.1 ml) were added to 0.7 ml of ascorbate-molybdate reagent, which consists of 1 part of 10% ascorbic and 6 parts of 0.42% (w/v) ammonium molybdate in 1 N H2SO4. Tubes were incubated at 45 °C for 20 min, and absorbance was determined at 820 nm.

Time-lapse Microscopy—HeLa cells were plated overnight in 35-mm culture dishes in DMEM and replaced with phenol red-free DMEM with 2',7'-dichlorofluorescin diacetate (DCF-DA), followed by treatment with GzmM (1 μM) and Ad. Images were taken every 2 min by Olympus IX71 microscope (29). Measurement of Intracellular ROS—Intracellular ROS production was monitored by incubating HeLa cells with 10 μM DCF-DA at 37 °C for 30 min. Unincorporated DCF-DA was removed through complete washing with phosphate-buffered saline before loading GzmM with Ad. Fluorescence was measured using a flow cytometer (FACSCalibur). 200 μM H2O2-treated cells were used as a positive control.

Apoptosis and Cytochrome c Release Assay—Phosphatidylserine externalization was stained with Annexin V-fluorescein isothiocyanate labeling and assessed with flow cytometer. For the analysis of cyt c release, HeLa cells (1 × 106) were treated with GzmM plus Ad at the indicated times. Cells were washed twice with PBS and resuspended in 100 μl of digitonin lysis
buffer (80 mM KCl, 250 mM sucrose, 0.02% digitonin) for 5 min (18). The supernatants and the pellets were resolved on 15% SDS-PAGE and detected by immunoblotting using cyt c antibody.

Laser Scanning Confocal Microscopy—HeLa cells were grown overnight to subconfluence at 37 °C in 8-well chamber slides coated with rat collagen I (BD FalconTM) and incubated with 500 nM MitoTracker (Molecular Probes) for 30 min according to the manufacturer’s instruction. Cells were treated with 1 μM GzmM in the presence or absence of Ad for 4 h, washed, and fixed with 4% paraformaldehyde for 20 min at room temperature and permeabilized with 0.1% Triton X-100 for another 20 min, the cells were incubated at room temperature for 1 h with 5 μg/ml anti-cyt c mAb (clone 6H2.B4; Pharmingen), 50 μg/ml donkey serum and 100 μg/ml RNase I. The cells were stained with Alexa 488-conjugated donkey antimouse antibody. The cells were then stained with 0.1 μg/ml Hoechst. The slides were mounted with ProLong Antifade reagent and observed using laser scanning confocal microscopy (Olympus FV500 microscope).

Silencing and Overexpression of TRAP1—Three pairs of RNA sequences against TRAP1 for RNAi were designed based on pSUPER system instructions (Oligoengine) and cloned into pSUPER-puro that expresses 19-nt hairpin-type short hairpin RNAs (shRNAs) with a 9-nt loop, as described previously (30). TRAP1 shRNA-encoding sequences were as follows: shRNA1: 5’-ACATGAGTCCAGGGCAAGTTCTACAGACTCGGCCCTGAACCTCATGT-3’ (sense) and 5’-AAAAAAGTTTCAGGCCGAGTCTCCTTT-GAATTGCTGTACTTTTTT-3’ (antisense); shRNA2: 5’-GTACAGCAACATTCTGTCAGCTAGAAGAGACGGTGACG-AGATTGCTGTACTTTTTT-3’(sense) and 5’-AAAAAAGTT-ACAGCAACATTCTGTCAGCTAGAAGAGACGGTGACG-AGATTGCTGTACTTTTTT-3’ (antisense); shRNA3: 5’-ACATGAGTCCAGGGCAAGTTCTACAGACTCGGCCCTGAACCTCATGT-3’ (sense) and 5’-AAAAAAGTTTCAGGCCGAGTCTCCTTT-GAATTGCTGTACTTTTTT-3’ (antisense). The inserted shRNAs were confirmed by DNA sequencing. HeLa cells were transfected using Lipofectamine 2000 (Invitrogen) as described by the manufacturer. Cells with silenced TRAP1 were selected with puromycin. Empty vectors were used as a control. For TRAP1 overexpression, HeLa cells were transfected with either empty vector pCMV-HA or pCMV-HA-TRAP1 for 3 days.

RESULTS

GzmM Targets Mitochondria and Causes Loss of ∆Ψ—We previously demonstrated GzmM induces caspase-dependent apoptosis (13). Kelly et al. (12) reported GzmM induces caspase-independent cell death, which changed the morphology of mitochondria to be rounded but not to be dilated. We wanted to verify whether mitochondria are involved in GzmM-mediated apoptosis. To investigate whether GzmM provokes morphological changes of mitochondria, 1 μM GzmM was loaded with Ad into HeLa cells at 37 °C for 4 h and visualized by electron microscopy. GzmM plus Ad treatment induced profound mitochondrial swelling with loss of cristae structures (Fig. 1). The mitochondria of mock-treated cells showed normal features with a condensed state and narrow cristae. The mitochondria of cells treated with S-AgzmM plus Ad or GzmM alone had no effect (Fig. 1 and not shown). Similar results were obtained by loading GzmM with PFP (data not shown).

Mitochondrial functions are dependent on the maintenance of ∆Ψ (31). Loss of ∆Ψ is likely to contribute to the death of cells (32). To assess whether GzmM causes ∆Ψ collapse, Jurkat cells were treated with GzmM plus Ad and analyzed by FACS analysis. Cells loaded with GzmM plus Ad showed a dose-dependent decrease of ∆Ψ, assayed by the change in fluorescence of the sensitive dye 3,3’-dihexyloxacarbocyanine iodide DiOC6 (3) (2A). 0.25 μM GzmM started to initiate significant reduction of ∆Ψ. Inactive S-AgzmM plus Ad or mock-treated cells were without effect. An uncoupler of oxidative phosphorylation carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) was used to treat cells as a positive control. GzmM-induced ∆Ψ reduction was also in a time-dependent manner (Fig. 2B). 1 μM

FIGURE 1. GzmM causes mitochondrial swelling of target cells. HeLa cells were incubated with 1 μM GzmM and Ad at 37 °C for 4 h and detected by a high-magnification transmission electron microscopy (×6500). The normal and inflated mitochondria are indicated with arrows.

FIGURE 2. GzmM initiates loss of ∆Ψ. Jurkat cells were treated for the indicated doses of GzmM or S-AgzmM(S-A) for 4 h in the presence of Ad (100 pfu/ml) at 37 °C (A) or the indicated times with 1 μM GzmM plus Ad (B). The classic uncoupler of oxidative phosphorylation CCCP (10 μM) was used as a positive control. Changes in ∆Ψ were determined by 20 nM DiOC6 (3). 20 μM CsA was used to treat cells prior to GzmM loading. These data are representative of at least three independent experiments.
HSP75/TRAP1 Protects GzmM-mediated Apoptosis

GzmM plus Ad initiated a dramatic decrease in ΔΨ within 1 h. By 4 h, ΔΨ was completely collapsed. GzmM and Ad alone or S-AGzmM had little effect. PT pore can mediate mitochondrial swelling and depolarization during the course of apoptosis. We next investigated whether the PT pore inhibitor cyclosporine A (CsA) was capable of inhibiting the loss of ΔΨ induced by GzmM. CsA significantly inhibited the loss of mitochondrial ΔΨ induced by GzmM. These results indicate GzmM causes loss of ΔΨ through disruption of the PT pore.

GzmM Induces a Rapid Increase of Intracellular ROS—ROS production has been identified as an early event undergoing apoptosis induced by a variety of stimuli. Superfluous ROS cause mitochondrial damage as well as nuclear DNA damage. Mitochondria are the major source of intracellular ROS (33). GzmA induces a rapid increase of ROS and mitochondrial transmembrane potential loss leading to caspase-independent death (21). We next wanted to determine whether ROS is accumulated during GzmM-mediated cytolysis. ROS production was detected using the dye DCF that is a nonfluorescent cell-permeant compound. Once entering a cell, it is degraded by endogenous esterases and no longer diffuses out of the cell. De-esterified products become the fluorescent compound 2',7'-dichlorofluoroscein upon oxidation by ROS. To detect ROS accumulation in GzmM-induced death, HeLa cells were treated with various amounts of GzmM plus Ad as measured by detection of the conversion of DCF to 2',7'-dichlorofluorescin. 0.25 μM GzmM began to trigger ROS production within a 1-h treatment as measured by increase in mean fluorescence intensity (MFI) of the ROS indicator dye (Fig. 3A). GzmM augmented ROS generation with increasing concentrations. 1 μM GzmM reached a high peak for ROS production (MFI: 59.6). ROS accumulation required GzmM delivery by Ad. GzmM or Ad alone had no effect. Inactive mutant GzmM (S-AGzmM) plus Ad did not trigger ROS generation (not shown). H2O2-treated cells were used as a positive control. To further verify ROS generation induced by GzmM, time-lapse microscopy was used to visualize ROS production at a single cell level. HeLa cells were incubated in the presence of GzmM plus Ad, fluorescence staining dynamically condensed during induction of cell death (Fig. 3, B and C). GzmM and Ad alone treated cells were undetectable. One cell was chosen for detection of ROS generation by photographing every 2 min. ROS was produced early and increased over time, which was consistent with the above observations by FACS. H2O2 treated cells were used as a positive control. These data are representative of three separate experiments.

GzmM Directly Cleaves TRAP1—To investigate whether TRAP1 participates in GzmM-induced apoptosis, nanomolar concentrations of GzmM were incubated with recombinant TRAP1 (rTRAP1) at 37 °C for 2 h. GzmM began to degrade TRAP1 at a nanomolar concentration of 50 nM (Fig. 4A). rTRAP1 began to degrade within 10 min with 0.5 μM GzmM treatment. Inactive S-AGzmM did not cause TRAP1 degradation. Neither caspase3 nor caspase 8 cut rTRAP1 (data not shown). We detected TRAP1 degradation in cytoplasmic lysates of HeLa cells. Native TRAP1 (2 × 10^5 cell equivalents) was almost cleaved at the dose of 1.0 μM GzmM at 37° for 2 h (Fig. 4B). GzmM began to degrade TRAP1 at a very early time of 10 min. The full-length of TRAP1 was completely degraded by 2 h. S-AGzmM was without effect on recombinant or native form of TRAP1. These data indicate TRAP1 cleavage requires enzymatic activity of GzmM.

To further verify TRAP1 processing is physiologically relevant, HeLa cells were treated with 1 μM GzmM in the presence of Ad. TRAP1 was cleaved in GzmM/Ad-loaded cells by 2 h (Fig. 4C). After 6 h, TRAP1 was completely cleaved. GzmM and Ad alone or S-AGzmM plus Ad failed to degrade TRAP1. The same blot was stripped and reprobed for β-actin. β-Actin was unchanged as a good loading control. The GzmM concentration required to cut TRAP1 in vivo is comparable to that required to induce cell death and DNA damage (13). Therefore, TRAP1 is a direct physiological substrate of GzmM in vivo.
**HSP75/TRAP1 Protects GzmM-mediated Apoptosis**

These plasmids were separately transfected into HeLa cells. After 3 days, siRNA1 and siRNA2 each silenced TRAP1 expression by 60–70%; whereas siRNA3 had little effect on TRAP1 expression (Fig. 6A). pSUPER-TRAP1-shRNA1 stable cell lines were established by puromycin selection. TRAP1 was almost undetectable through immunoblotting. HeLa cells transfected with pSUPER empty vector were unchanged for expression of TRAP1.

With 50 μM H$_2$O$_2$ treatment, TRAP1 silenced HeLa cells got 34.6% ROS-positive. While only 11.9% control cells transfected with empty vector were ROS positive (Fig. 6B). Similar results were obtained with treatment of 100 μM H$_2$O$_2$. To further look at whether TRAP1 silencing enhances GzmM-induced ROS accumulation, TRAP1-silenced HeLa cells were loaded with GzmM plus Ad. ROS generation dramatically increased in TRAP1 silenced HeLa cells compared with cells transfected by GzmM or Ad alone. ROS levels were increased in parallel with ROS generation (28.9 μM: 22.9 versus 7.0%; 0.5 μM: 80.2 versus 31.2%; 1 μM: 98.9 versus 47.0%) (Fig. 6C). Cells treated with GzmM or Ad alone just got comparable levels of ROS. These results indicate that TRAP1 cleavage enhances ROS generation during GzmM-induced apoptosis.

**TRAP1 Silencing Accelerates Cytochrome c Release and GzmM-induced Death**—Cyt c release from mitochondria appears to be an early event during apoptosis induced by a variety of stimuli (35). Cytosolic cytochrome c together with Apaf-1 and procaspase-9 in a ATP-dependent manner forms apoptosisosome that causes caspase activation to orchestrate the biochemical execution of cells (36). Intracellular ROS arise prior to cyt c release during activation of several apoptotic pathways. GzmM can induce a rapid increase of intracellular ROS, we further detected whether GzmM induces cyt c release from mitochondria. Cyt c was released from mitochondria in HeLa cells treated with GzmM and Ad visualized through confocal microscopy (Fig. 7A). Cyt c was not released in response to treatment with GzmM and Ad alone or S-AGzmM plus Ad (data not shown).

We next wanted to test whether TRAP1 affects GzmM-induced cyt c release. HeLa cells with silenced TRAP1 were treated with GzmM plus Ad at 37 °C for different time points. Cyt c release occurred in HeLa cells with silenced TRAP1 at earlier time compared with those with transfection by empty vectors after treatment with GzmM and Ad (Fig. 7B). Cyt c was not detected in supernatants of control cells under identical conditions.
conditions until 3h. These data indicate TRAP1 silencing can accelerate cyt c release in GzmM-induced death.

We next verified whether TRAP1 can protect cells from GzmM-mediated cytolysis. Cells with silenced TRAP1 or empty vector control cells were treated with GzmM and Ad and assayed by Annexin V staining. Control cells obtained 40 ± 2% Annexin V positive. Annexin V positive rate in silenced TRAP1 cells increased (62 ± 3%) (p < 0.02) (Fig. 7C). To examine whether ROS is involved in GzmM-induced death, the cells were pretreated with the superoxide scavenger Tiron (50 mM) for 30 min, and treated with GzmM plus Ad. Tiron treatment can inhibit GzmM-induced death both in TRAP1 silenced or control cells (TRAP1 silencing: 19 ± 3% versus 62 ± 3%; control cells: 18 ± 2% versus 40 ± 2%).

Overexpression of TRAP1 Protects Cells from GzmM-induced Apoptosis through Attenuating ROS Generation—To further verify the role of TRAP1 in GzmM-induced...
GzmM induces typical apoptosis depending on caspase activation and CAD-mediated DNA fragmentation (13). However its molecular machinery of death is less defined. Here we demonstrate GzmM-induced apoptosis is dependent on mitochondrial damage. GzmM induces loss of $\Delta \Psi$ and a rapid accumulation of intracellular ROS. TRAP1 acts as an important ROS regulator to antagonize ROS generation. Cleavage of TRAP1 by GzmM might be central to ROS generation.

Mitochondria play an important role in the caspase-dependent death pathway, in which damage of the mitochondrial outer membrane (MOM) integrity releases a number of key intermembrane proteins, such as cyt c, SMAC, HtrA2, AIF, and EndoG that are released into the cytosol undergoing apoptosis (39). These events are initiated by the opening of the PT pore (5). Opening of the PT pore triggers an increase of inner membrane permeability to ions and solutes, followed by net water influx toward the mitochondrial matrix, swelling of the organelle, and physiological disruption of its outer membrane, with the consequent release of proteins to the intermembrane space. Increase of ROS and loss of $\Delta \Psi$ are indicative of mitochondrial dysfunction, hallmarks of apoptotic mitochondrial damage. It is postulated that ROS and $\Delta \Psi$ collapse are early events in apoptosis that are involved in the opening of the PT pore of the inner mitochondrial membrane. Kelly et al. (12) found GzmM induces caspase-independent cell death. GzmM triggered mitochondria to be rounded but not cause loss of $\Delta \Psi$ and other functions. However we found GzmM induces mitochondrial swelling and collapse of $\Delta \Psi$ through PT pore opening. GzmB and GzmC can induce mitochondrial damage independently of the caspases (18, 19). Lieberman group showed ROS is critical in GzmA-induced caspase-independent death. ROS generation induced by GzmA is not inhibited by Bcl-2 overexpression or by pan caspase inhibitors (21). Superoxide scavengers can block apoptosis by GzmA or CTLs expressing GzmA and/or GzmB. These findings indicate ROS is central to cytolysis induced by cytolytic lymphocytes.

Kelly et al. (12) still showed GzmM does not cause ROS accumulation and release of cyt c. We found GzmM triggers a rapid increase of intracellular ROS by targeting mitochondria and confirmed it at a single cell level. Both the antioxidant NAC and the superoxide scavenger Tiron blocked ROS production that protected cells from GzmM-induced death (data not shown). We identified that a key heat shock protein 75 (TRAP1) is a physiological substrate of GzmM that is localized in mitochondria.
HSP75/TRAP1 Protects GzmM-mediated Apoptosis

...distribution of TRAP1. In this study, we found TRAP1 localizes in the mitochondria, which is consistent with the observation by Felts et al. (24). Cleavage by GzmM enhances a rapid increase of ROS. Cells with silenced TRAP1 expression are more prone to the generation of ROS, whereas cells overexpressing TRAP1 inhibit the production of ROS, which appears with similar dynamics to GzmM-induced cell death. We checked that other Gzms A, B, or K did not cleave TRAP1 (data not shown). Thus it suggests TRAP1 might be important to antagonize ROS accumulation in response to GzmM-mediated cell death.

ROS induce the opening of PT pore through oxidation-dependent mechanisms and are potent inducers of apoptosis (14). A cell is endowed with an extensive antioxidant defense system to combat ROS, either directly by interception or indirectly through reversal of oxidative damage. Once ROS overcome the defense systems of the cell, the redox homeostasis is altered, which leads to oxidative stress. HSPs are among the subset of oxidative stress-responsive proteins known to prevent protein aggregation. In addition, HSPs may directly regulate specific stress-responsive signaling pathways and may antagonize signaling cascades that result in apoptosis. HSP70 protects cells from a number of apoptotic stimuli, such as heat shock, radiation and oxidative stress. HSP90 appears to be involved in the inhibition of apoptosis by suppressing the cyt c-mediated oligomerization of Apaf-1 (34). HSP25 down-regulates PKC inhibition of apoptosis by suppressing the cyt c-mediated oligomerization of Apaf-1 (34). HSP25 down-regulates PKC inhibition of apoptosis by suppressing the cyt c-mediated oligomerization of Apaf-1 (34). HSP25 down-regulates PKC inhibition of apoptosis by suppressing the cyt c-mediated oligomerization of Apaf-1 (34). HSP25 down-regulates PKC inhibition of apoptosis by suppressing the cyt c-mediated oligomerization of Apaf-1 (34).

REFERENCES

1. Trapani, J. A., and Smyth, M. J. (2002) Nat. Rev. Immunol. 2, 735–747
2. Fan, Z., and Zhang, Q. (2005) Cell Mol. Immunol. 2, 259–264
3. Russell, J. H., and Ley, T. J. (2002) Annu. Rev. Immunol. 20, 323–370
4. Fan, Z., Beresford, P. J., Oh, D. Y., Zhang, D., and Lieberman, J. (2003) Cell 112, 659–672
5. Fan, Z., Beresford, P. J., Zhang, D., and Lieberman, J. (2002) Mol. Cell Biol. 22, 2810–2820
6. Lieberman, J., and Fan, Z. (2003) Curr. Opin. Immunol. 15, 553–559
7. Fan, Z., Beresford, P. J., Zhang, D., Xu, Z., Novina, C. D., Yoshida, A., Pommier, Y., and Lieberman, J. (2003) Nat. Immunol. 4, 145–153
8. Bots, M., and Medema, J. P. (2006) J. Cell Science 119, 5011–5014
9. Grossman, W. J., Revell, P. A., Lu, Z. H., Johnson, H., Bredemeyer, A. J., and Ley, T. J. (2003) Curr. Opin. Immunol. 15, 544–552
10. Smyth, M. J., Wiltrout, T., Trapani, J. A., Ottaway, K. S., Sowder, R., Henderson, L. E., Kam, C. M., Powers, J. C., Young, H. A., and Sayers, T. J. (1992) J. Biol. Chem. 267, 24418–24425
11. Sayers, T. J., Brooks, A. D., Ward, J. M., Hoshino, T., Bene, W. E., Wiegand, G. W., Kelly, J. M., and Smyth, M. J. (2001) J. Immunol. 166, 765–771
12. Kelly, J. M., Waterhouse, N. J., Cretney, E., Browne, K. A., Ellis, S., Trapani, J. A., and Smyth, M. J. (2004) J. Biol. Chem. 279, 22236–22242
13. Lu, H., Hou, Q., Zhao, T., Zhang, H., Zhang, Q., Wu, L., and Fan, Z. (2006) J. Immunol. 177, 1117–1178
14. Danial, N. N., and Korsmeyer, S. J. (2004) Cell 116, 205–219
15. Alimonti, J. B., Shi, L., Baijal, P. K., and Greenberg, A. H. (2001) J. Biol. Chem. 276, 6974–6982
16. Heibein, J. A., Goping, I. S., Barry, M., Pinkoski, M. J., Shore, G. C., Green, D. R., and Bleackley, R. C. (2000) J. Exp. Med. 192, 1391–1402
17. Barry, M., Heibein, J. A., Pinkoski, M. J., Lee, S. F., Moyer, R. W., Green, D. R., and Bleackley, R. C. (2000) Mol. Cell Biol. 20, 3781–3794
18. Heibein, J. A., Barry, M., Motyka, B., and Bleackley, R. C. (1999) J. Immunol. 163, 4683–4693
19. Johnson, H., Scorrano, L., Korsmeyer, S. J., and Ley, T. J. (2003) Blood 101, 3093–3101
20. MacDonald, G., Shi, L., Vande Velde, C., Lieberman, J., and Greenberg, A. H. (1999) J. Exp. Med. 189, 131–144
21. Martinvael, D., Zhu, P., and Lieberman, J. (2005) Immunity 22, 355–370
22. Song, H. Y., Dunbar, J. D., Zhang, Y. X., Guo, D., and Donner, D. B. (1995) J. Biol. Chem. 270, 3574–3581
23. Chen, C. F., Chen, Y., Dai, K., Chen, P. L., Riley, D. J., and Lee, W. H. (1996) Mol. Cell Biol. 16, 4691–4699
24. Felts, S. J., Owen, B. A., Nguyen, P., Trepel, J., Donner, D. B., and Toft, D. O. (2000) J. Biol. Chem. 275, 3305–3312
25. Masuda, Y., Shima, G., Aiuchi, T., Horie, M., Hori, K., Nakajo, S., Kajimoto, S., Shibayama-Imazu, T., and Nakaya, K. (2004) J. Biol. Chem. 279, 42503–42515
26. Im, C. N., Lee, J. S., Zheng, Y., and Seo, J. S. (2007) J. Cell. Biochem. 100, 474–486
27. Zhao, T., Zhang, H., Guo, Y., and Fan, Z. (2007) J. Biol. Chem. 282, 12104–12111
28. Kempaiah, R. K., and Srinivasan, K. (2006) J. Nutr. Biochem. 17, 471–478
29. Waterhouse, N. J., Sedelies, K. A., Sutton, V. R., Pinkoski, M. J., Thia, K. Y., Johnstone, R., Bird, P. I., Green, D. R., and Trapani, J. A. (2006) Cell Death Differ. 13, 607–618
30. Brummelkamp, T. R., Bernards, R., and Agami, R. (2002) Science 296, 550–553
31. Voisine, C., Craig, E. A., Zufall, N., von Ahsen, O., Pfanner, N., and Voos, W. (1999) Cell 97, 565–574
32. Ricci, I. E., Gottlieb, R. A., and Green, D. R. (2003) J. Cell. Biol. 160, 65–75
33. Esposito, L. A., Melov, S., Panov, A., Cottrell, B. A., and Wallace, D. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 4820–4825
34. Pandey, P., Saleh, A., Nakazawa, A., Kumar, S., Srinivasula, S. M., Kumar, V., Weichselbaum, R., Nalini, C., Alnemri, E. S., Kufe, D., and Kharbanda, S. (2000) EMBO J. 19, 4310–4322
35. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newman, D. D. (1997) Science 275, 1132–1136
36. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 479–489
37. Fan, Z., Yu, P., Wang, Y., Wang, Y., Fu, M. L., Liu, W., Sun, Y., and Fu, Y. X. (2006) Blood 107, 1342–1351
38. Suck, G., Branch, D. R., Smyth, J. M., Miller, R. G., Vergidis, J., Fahim, S., and Keating, A. (2005) Exp. Hematol. 33, 1160–1171
39. Jiang, X., and Wang, X. (2004) Annu. Rev. Biochem. 73, 87–106
40. Lee, Y. J., Lee, D. H., Cho, C. K., Chung, H. Y., Ba, S., Jho, G. I., Soh, J. W., Jeoung, D. I., Lee, S. J., and Lee, Y. S. (2005) Oncogene 24, 3715–3725

Acknowledgments—We thank Drs. D. O. Toft, S. J. Felts, and Guifang Chen for their reagents and Chunhun Liu, Youli Xu, Lei Sun, and Yan Teng for their technical help.